Selection panel and principles

Selection panel
EHA Board — Margarita Guenova
EHA Board — Jose Maria Ribera
Community and Stakeholder Committee — Darko Antic
Diversity, Equity, and Inclusion Taskforce — Mihnea-Alexandru Gaman
Education Committee — Jose Tomás Navarro Ferrando
European Affairs Committee — Julio Delgado
Patient Advocacy Committee — to be…

Look back at EHA2024

Register for EHA2025

Get ready to make new connections in Milan from June 12–15, 2025. Register now for EHA's reimagined Congress experience.

Accommodation

Welcome to the Hotel Accommodation page for the EHA2025 Congress. Hotel Information and Official Housing Bureau

INTERPLAN AG is the official housing bureau for the EHA2025 Congress.

Evaluation of a single 1.000 mg iron dose as ferric carboxymaltose (FCM) for fatigue treatment in Iron deficient women – PREFER

Fatigue and iron deficiency are prevalent among women of childbearing age. This randomised, placebo-controlled study evaluated the effect of a single intravenous 1.

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

SWG Educational Activities

EICMLThe 2023 EICML meeting took place in Naples in May 2023. Fifty-five physicians and scientists met at the Palazzo Alabardieri in central Naples to spend two days discussing emerging data and developing collaborations.

Mini-hormone fights iron

Iron overload commonly leads to organ damage and even death. Currently available treatments for iron overload are burdensome or cause side effects.

First randomized evidence for kinase inhibitor activity in acute myeloid leukemia

Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).